Purchase this article with an account.
M.R. Wilkins, J.K. G. Dart; Mycophenolate Mofetil for the Treatment of Severe Inflammatory External Eye Disease Conditions . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2664.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To ascertain the benefits and side effects from using Mycophenolate mofetil (MMF) to treat severe inflammatory external eye disease
We performed a retrospective case note review of all patients who had received MMF for severe inflammatory external eye disease at Moorfields Eye Hospital. Patients were identified from an immunosuppression database and from the hospital’s electronic patient record. Patients receiving MMF as prophylaxis for corneal graft rejection were excluded.
26 patients were identified, their mean age was 60. All started MMF either because other systemic immunosuppressants had failed to control the inflammation or had not been tolerated. Diagnoses and whether the inflammation was controlled are given in table 1.
Mycophenolate mofetil is quite well tolerated and was successful in controlling inflammation in 61%, and partially successful in a further 12%, of patients with this group of severe inflammatory external eye diseases that had been uncontrolled by other systemic immunosuppressant agents due to drug intolerance or treatment failure.
This PDF is available to Subscribers Only